DiscGenics is honored to announce that it was one of three Biotech finalists for the 12th annual Utah Innovation Awards. The finalists were chosen by 60 industry experts and professionals from the Utah’s business, government, and higher educations communities. More than 100 nominations were considered on a wide range of criteria including novelty, market need, market disruption and potential/current economic impact.
About DiscGenics, Inc.
DiscGenics is a privately funded biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. We are currently developing IDCT, a novel off-the-shelf injectable therapeutic based on regenerative medicine and progenitor cell science to treat pain associated with degenerative disc disease. News and other information on the company are available at http://www.DiscGenics.com.
Flagg Flanagan, Chief Executive Officer